📊 PRLD Key Takeaways
Is Prelude Therapeutics Inc (PRLD) a Good Investment?
Pre-profitability biotech company burning cash at unsustainable rate (~$56M annually) against limited cash reserves ($35.3M), creating acute going-concern risk within 12 months. Revenue growth of +73.4% YoY demonstrates operational traction, but from an insufficient base relative to operating losses of -$104.6M.
Why Buy Prelude Therapeutics Inc Stock? PRLD Key Strengths
- Strong revenue growth trajectory at +73.4% YoY indicates emerging commercial traction
- Zero long-term debt and debt/equity ratio of 0.00x provide financial flexibility
- Improving diluted EPS of -$1.29 (+23.2% YoY) shows operational margin improvement trajectory
PRLD Stock Risks: Prelude Therapeutics Inc Investment Risks
- Acute liquidity crisis: $35.3M cash runway at -$56.3M annual operating burn rate provides <12 months of operations
- Massive operating losses of -$104.6M against $12.1M revenue indicate pre-commercial stage with no near-term path to profitability
- Free cash flow of -$56.4M with -464.3% FCF margin demonstrates company is not operationally self-sustaining
Key Metrics to Watch
- Operating cash burn rate and months of cash runway remaining
- Gross margin achievement once revenue base scales
- Capital raise announcements or strategic partnership financing to extend liquidity runway
Prelude Therapeutics Inc (PRLD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Prelude Therapeutics Inc presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
PRLD Profit Margin, ROE & Profitability Analysis
PRLD vs Healthcare Sector: How Prelude Therapeutics Inc Compares
How Prelude Therapeutics Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Prelude Therapeutics Inc Stock Overvalued? PRLD Valuation Analysis 2026
Based on fundamental analysis, Prelude Therapeutics Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Prelude Therapeutics Inc Balance Sheet: PRLD Debt, Cash & Liquidity
PRLD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Prelude Therapeutics Inc's revenue has grown significantly by 73% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.68 indicates the company is currently unprofitable.
PRLD Revenue Growth, EPS Growth & YoY Performance
PRLD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.0M | -$19.7M | $-0.26 |
| Q3 2024 | $3.0M | -$27.7M | $-0.43 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Prelude Therapeutics Inc Dividends, Buybacks & Capital Allocation
PRLD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Prelude Therapeutics Inc (CIK: 0001678660)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PRLD
What is the AI rating for PRLD?
Prelude Therapeutics Inc (PRLD) has an AI rating of SELL with 70% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PRLD's key strengths?
Claude: Strong revenue growth trajectory at +73.4% YoY indicates emerging commercial traction. Zero long-term debt and debt/equity ratio of 0.00x provide financial flexibility.
What are the risks of investing in PRLD?
Claude: Acute liquidity crisis: $35.3M cash runway at -$56.3M annual operating burn rate provides <12 months of operations. Massive operating losses of -$104.6M against $12.1M revenue indicate pre-commercial stage with no near-term path to profitability.
What is PRLD's revenue and growth?
Prelude Therapeutics Inc reported revenue of $12.1M.
Does PRLD pay dividends?
Prelude Therapeutics Inc does not currently pay dividends.
Where can I find PRLD SEC filings?
Official SEC filings for Prelude Therapeutics Inc (CIK: 0001678660) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PRLD's EPS?
Prelude Therapeutics Inc has a diluted EPS of $-1.29.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PRLD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Prelude Therapeutics Inc has a SELL rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PRLD stock overvalued or undervalued?
Valuation metrics for PRLD: ROE of -145.0% (sector avg: 15%), net margin of -819.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PRLD stock in 2026?
Our dual AI analysis gives Prelude Therapeutics Inc a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PRLD's free cash flow?
Prelude Therapeutics Inc's operating cash flow is $-56.3M, with capital expenditures of $67.0K. FCF margin is -464.3%.
How does PRLD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -819.6% (avg: 12%), ROE -145.0% (avg: 15%), current ratio 1.99 (avg: 2).